Tower Research Capital LLC TRC Has $102,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX)

Tower Research Capital LLC TRC lifted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 442.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,138 shares of the biotechnology company’s stock after buying an additional 10,714 shares during the period. Tower Research Capital LLC TRC’s holdings in REGENXBIO were worth $102,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,510 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of REGENXBIO in the fourth quarter worth $54,000. Dynamic Technology Lab Private Ltd acquired a new position in REGENXBIO during the fourth quarter worth $79,000. Teacher Retirement System of Texas grew its position in REGENXBIO by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,088 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new stake in REGENXBIO in the 4th quarter valued at $97,000. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $7.13 on Friday. The business has a fifty day simple moving average of $7.29 and a two-hundred day simple moving average of $8.03. REGENXBIO Inc. has a 1 year low of $5.04 and a 1 year high of $16.85. The company has a market capitalization of $357.33 million, a price-to-earnings ratio of -1.42 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million. As a group, equities analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on RGNX. The Goldman Sachs Group reduced their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. HC Wainwright decreased their price target on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Monday, March 17th. Chardan Capital reiterated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, March 20th. Morgan Stanley raised their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, March 14th. Finally, Leerink Partners set a $24.00 price target on shares of REGENXBIO in a research report on Tuesday, March 18th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, REGENXBIO presently has an average rating of “Moderate Buy” and an average price target of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.